<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000257898"><TermName>tipifarnib</TermName><TermPronunciation>(tih-pee-FAR-nib)</TermPronunciation><TermDefinition><DefinitionText>A substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. Also called R115777 and Zarnestra.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000710208" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;tipifarnib&quot;" language="en" id="_3"/><MediaLink ref="CDR0000710207" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;tipifarnib&quot;" language="es" id="_4"/><SpanishTermName>tipifarnib</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de la leucemia mieloide aguda (LMA) y otros tipos de cáncer. Es un tipo de inhibidor de la farnesiltransferasa. También se llama R115777 y Zarnestra.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateLastModified>2006-05-10</DateLastModified></GlossaryTerm>
